On Wednesday, Shares of Banco Bradesco SA (ADR) (NYSE:BBD), gained 4.08% to $5.36, after Brazil’s budget deficit declined more than predictable in August.
Earlier Wednesday, Brazil’s central bank declared that the country’s primary deficit was 7.3 billion reais ($1.8 billion) last month, contrast to estimates for a gap of 11 billion reias by economists surveyed by Bloomberg. July’s gap was 10 billion reais, according to Bloomberg.
In early September, the S&P downgraded Brazil’s sovereign rating to junk due to the country’s budget deficit, which ultimately pushed Brazil’s real to an all-time low last week, Bloomberg stated.
Banco Bradesco S.A. (the Bank) is a commercial bank. The Bank offers a range of banking and financial products and services in Brazil and abroad to individuals, companies and local and international corporations and institutions. Its products and services include banking operations, such as loans and advances and deposit-taking, credit card issuance, purchasing consortiums, insurance, leasing, payment collection and processing, pension plans, asset management and brokerage services.
Shares of Huntsman Corporation (NYSE:HUN), inclined 3.75% to $9.68, during its last trading session.
Huntsman Corporation declared recently that its board of directors has authorized the repurchase of up to $150 million of the company’s common stock.
Peter R Huntsman, President and CEO, commented: “This share repurchase program is an expression of confidence in the company’s long term future and ability to generate further shareholder value. We are reviewing our current capital plan for 2016 and 2017 and believe we can reduce capital expenditures and improve working capital commensurate with the costs of the repurchase program. As we complete our remaining cost reduction objectives of more than $100 million and complete various capital projects early next year, we will see the benefits of these measures as well.”
Huntsman Corporation (Huntsman) is a manufacturer of differentiated organic chemical products and of inorganic chemical products. The Company is also engaged in performance additives and titanium dioxide business. The Company also offers titanium dioxide, a white pigment derived from titanium bearing ores; functional additives made from barium and zinc-based inorganics; color pigments made from synthetic iron-oxide and other inorganic pigments; timber treatment wood protection chemicals; water treatment products, and specialty automotive molded components.
Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), inclined 2.49% to $56.45, during its last trading session.
Teva Pharmaceutical Industries declared recently that Lancet Neurology published online, as back-to-back articles, the results from two Phase 2b studies of TEV-48125, a monoclonal anti-calcitonin gene-related peptide (CGRP) antibody investigational treatment for the prevention of chronic migraine and high frequency episodic migraine (HFEM). The Lancet Neurology ranks first among 194 journals in the clinical neurology category (2013 Journal Citation Reports®, Thomson Reuters 2014).
The Phase 2b clinical development program consistently met all primary and secondary efficacy and safety endpoints for TEV-48125 in 564 patients and across multiple doses. Clinical improvements were exhibited after a single administration of all tested doses of TEV-48125 in both episodic and chronic migraine studies.
These results were achieved in the presence of patients being allowed to remain on existing migraine prevention therapy and the results demonstrated noteworthy separation in favor of TEV-48125 even in patients considered to be failing current optimal therapy.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Company’s generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services.
Finally, Fiat Chrysler Automobiles NV (NYSE:FCAU), ended its last trade with 8.19% gain, and closed at $13.21, as employees represented by the United Auto Workers will likely reject a new four-year contract that would improvement wages for members and narrow the pay gap for second-tier workers.
Around two-thirds of the automobile manufacturer’s 40,000 employees have voted on the pact, and the Belvidere, IL plant that makes the Dodge Dart votes recently, Bloomberg reports. Few have approved the contract, and a Detroit Free Press analysis published on Wednesday reveals that the deal will not pass.
Rejection of the deal, which was initially reached on September 16, could ultimately result in a less desirable contract for the union, Art Wheaton, professor of labor at Cornell University, told Bloomberg.
Fiat Chrysler Automobiles N.V., an automotive group, designs, engineers, manufactures, distributes, and sells vehicles and components. It offers passenger cars, light trucks, and light commercial vehicles under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia, and Ram brand names, as well as after-sales services and parts under the Mopar brand name. The company also produces and sells luxury sport cars under the Ferrari and Maserati brands.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
